Steroid receptor assays in human breast tumours
Read Online
Share

Steroid receptor assays in human breast tumours methodological and clinical aspects

  • 502 Want to read
  • ·
  • 80 Currently reading

Published by Alpha Omega in Cardiff, Wales .
Written in English

Subjects:

  • Breast -- Cancer,
  • Breast -- Tumors,
  • Breast Neoplasms -- analysis -- essays.,
  • Receptors, Steroid -- analysis -- essays.,
  • Steroid hormones -- Receptors

Book details:

Edition Notes

Other titlesBreast receptors
Statementeditor, R. J. B. King.
ContributionsKing, Roger John Benjamin,
Classifications
LC ClassificationsRC280B8 S76
The Physical Object
Pagination101 p. :
Number of Pages101
ID Numbers
Open LibraryOL18982797M
ISBN 100900663081

Download Steroid receptor assays in human breast tumours

PDF EPUB FB2 MOBI RTF

  This chapter discusses the endocrine therapy and the use of steroid receptors in human breast cancer. The chapter highlights the information that estrogen receptor (ER) provides in the primary tumor. ER assays select a subset of patients who recur early and have poor by: Several papers dealing with the clinical relevance of steroid hormone receptors in breast cancer have already been published. However, no publication has overviewed studies currently being conducted in Europe, nor is there a register of the european centers performing receptor assays. It has been our purpose to fill these gaps. Several papers dealing with the clinical relevance of steroid hormone receptors in breast cancer have already been published. However, no publication has overviewed studies currently being conducted in Europe, nor is there a register of the european centers performing receptor assays. R. J. B. King, Oestrogen and Progestin Receptors as Markers for the Behaviour of Human Breast Tumours, Biochemical and Biological Markers of Neoplastic Transformation, /, (), ().

Estrogen and progesterone receptors (ER and PR) have now been studied in clinical breast cancer for more than 20 years. Positive receptor status correlates with favorable prognostic features including a lower rate of cell proliferation and histologic evidence of tumor differentiation. During the first several years after diagnosis, patients with ER-positive tumors tend to have a lower. There is general agreement that a valid histologic method for detection of steroid receptors in human breast cancer would be a valuable clinical tool. Localization Of Putative Steroid Receptors book. Volume II: Clinically Oriented Studies Morphologic Detection of Multiple Steroid Binding Sites in Breast Cancer by Histochemistry and By.   RECEPTOR ASSAYS. Tissue preparation and receptor analysis was performed as described earlier. The samples where assayed by the Dextran-Coated-Charcoal-Method according to the standards for the assessment of hormone receptors in human breast cancer by the EORTYC. The borderline between receptor positive and receptor negative tumor samples was. assess tumor heterogeneity is imaging using receptor-targeted ra-diopharmaceuticals. Noninvasive imaging is a useful approach for visual assessment and quantitative measurement of steroid hormone receptors both in primary breast cancer and across metastatic sites of disease. The techniques used for steroid receptor imaging have focused pre-.

Histochemical assay of estrogen and progesterone receptors in breast cancer: Correlation with biochemical assays and patients' response to endocrine therapies Louis P. . Resad Pasic, Benjamin Djulbegovic, James L. Wittliff, Comparison of sex steroid receptor determinations in human breast cancer by enzyme immunoassay and radioligand binding, Journal of Clinical Laboratory Analysis, /jcla, 4, 6, (), (). Chamnes GC, McGuire WL () Steroid receptor assay methods in human breast cancer. In: Thompson EB, Lippman ME (eds) Steroid receptors and the management ov cancer. CRC, Boca Raton, pp 3–30 Google Scholar. to RNA isolation. Frozen human breast tumor specimens, stored at°C,were obtained from the San Antonio Breast Tumor Bank and consist of tissue remaining after receptor assays performed in the San Antonio clinical receptor laboratory; no clinical follow-up .